Workit Health vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Virtual addiction treatment platform for alcohol and opioid use disorder, Ann Arbor MI, raised $118M+. Combines medication-assisted treatment with digital coaching.
About
Workit Health is an Ann Arbor, Michigan-based virtual addiction treatment company founded in 2015 that provides evidence-based treatment for opioid use disorder (OUD) and alcohol use disorder (AUD) through a telehealth platform. The company has raised over $118 million and operates in multiple US states, delivering medication-assisted treatment (MAT) including buprenorphine prescribing alongside behavioral health coaching and peer support — all accessible from a member's smartphone.\n\nWorkit Health's model addresses the primary barriers to addiction treatment: stigma, geographic access, and cost. By delivering care via telehealth, the platform reaches patients in rural areas and communities where addiction specialists are scarce. The company accepts Medicaid in multiple states, making treatment accessible to lower-income patients who are disproportionately impacted by the opioid crisis. Clinicians on the platform conduct initial assessments by video, prescribe medications electronically, and monitor patient progress through regular virtual check-ins and app-based engagement tools.\n\nThe platform includes a structured digital program with skills-based modules covering triggers, coping strategies, and recovery maintenance, delivered alongside clinical care. Workit Health competes with Bicycle Health, Ophelia, and Boulder Care in the virtual MAT market. The company has expanded to serve employers and health plans as well as direct consumers, positioning it as both a consumer-facing addiction recovery resource and a value-based care solution for payers managing high-cost substance use disorder populations.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.